Literature DB >> 29622884

Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib.

Prasanth Ganesan1, Thanda Joshua1, Shirley Sundersingh2, Tenali Gnana Sagar1.   

Abstract

Entities:  

Keywords:  ALK; Anaplastic large cell lymphoma ALK+ve; Crizotinib; Targeted therapy

Year:  2017        PMID： 29622884      PMCID： PMC5884998          DOI： 10.1007/s12288-017-0889-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  4 in total

1.  Crizotinib in anaplastic large-cell lymphoma.

Authors:  Carlo Gambacorti-Passerini; Cristina Messa; Enrico M Pogliani
Journal:  N Engl J Med       Date:  2011-02-24       Impact factor: 91.245

Review 2.  Anaplastic large cell lymphoma, ALK-positive.

Authors:  Andrés J M Ferreri; Silvia Govi; Stefano A Pileri; Kerry J Savage
Journal:  Crit Rev Oncol Hematol       Date:  2012-03-21       Impact factor: 6.312

3.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

4.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.